By Dhirendra Tripathi

Investing.com – Novavax stock (NASDAQ:) climbed 9% Thursday after the company applied with the World Health Organization for emergency approval to its much-delayed Covid-19 vaccine.

Following the submission of the two companies to India’s Drugs Controller General, the application is jointly made with Serum Institute of India.

For exports to Covax countries, the WHO must grant an emergency license. This facility was created to distribute and allocate vaccines fairly to all countries.

Novavax, SII and AstraZeneca completed last month the submission of modules to Indian and Indonesian regulatory agencies for the start of vaccine review. SII is AstraZeneca’s world-leading vaccine maker by production capacity. 

The submission of the application comes after several months of delay that has seen the likes of Pfizer (NYSE:)-BioNTech (NASDAQ:), Moderna (NASDAQ:), AstraZeneca (NASDAQ:) and Gamaleya (Sputnik) race ahead in providing vaccines to millions of people worldwide.  

NVXCoV2373 is a candidate protein-based vaccine. It was created from the genetic sequences of the original coronavirus strain. This vaccine comes just as the virus has mutated and left its Delta strain the predominant strain in many countries around the globe.

Novavax’ recombinant microparticle technology enabled the creation of NVX-CoV2373. This vaccine was derived using coronavirus spike protein.

Novavax’ COVID-19 vaccine comes in ready-to use liquid form packaged in a vial that contains ten doses. Two 0.5ml intramuscular doses of vaccine are required 21 days apart. The vaccine is stored at 2°- 8° Celsius, enabling the use of existing vaccine supply and cold chain channels.